For adults with cHL whose cancer
has come back or spread after an autologous
stem cell transplant and treatment with
Adcetris® (brentuximab vedotin) or after
3 or more kinds of treatment including
an autologous stem cell transplant
Clinical Trial Results
Impressive Response Rates
Proven in Clinical Trials
or 179 of 258 patients had their tumors shrink or disappear completely
The clinical trials are ongoing.
About the Clinical Trials
OPDIVO was studied in and results were combined from two different clinical trials, which included
258 adult cHL patients whose cancer had come back
or spread after autologous stem cell transplant.
Most of these patients also had treatment with Adcetris® (brentuximab vedotin).
The two studies were designed to look at overall response rate and duration of response. Overall response rate is the percentage of patients who responded to treatment. These patients saw their tumors either shrink or disappear completely. The duration of response is the measure of how long the response lasts.
OPDIVO will not work for everyone. Individual results may vary.
How Long Did Patients Respond to OPDIVO in the Clinical Trials?
Of the 179 patients who responded
Of those who responded, 69% or 179 of 258 patients
were still responding to treatment when the data
With an average follow-up time of 6.7 months,
more than half of the patients who responded to OPDIVO
were still responding in the clinical trials.
The clinical trials are ongoing.
Select Important Facts
What are the serious side effects of OPDIVO?
OPDIVO can cause problems that can sometimes become serious or
life-threatening and can lead to death. Serious side effects may include lung problems (pneumonitis); intestinal problems (colitis) that can lead to tears or holes in your intestine; liver problems (hepatitis); hormone gland problems (especially the thyroid, pituitary, adrenal glands, and pancreas); kidney problems, including nephritis and kidney failure; skin problems; inflammation of the brain (encephalitis); problems in other organs; severe infusion reactions: and complications of stem cell transplant that uses donor stem cells (allogeneic).
Of the 258 patients included from the two clinical trials,
a smaller group of 95 patients was also studied.
These patients previously had an autologous
stem cell transplant and received
Adcetris® (brentuximab vedotin) after the transplant.
(63 of 95) saw an improvement in
their condition with OPDIVO
In this group of 95 patients, half of the 63 patients
who responded to OPDIVO saw tumors shrink
or disappear for at least
(median duration of response was
range 0.0+ to 23.1+ months)
What are the most common side effects of OPDIVO?
The most common side effects of OPDIVO when used alone include:
- feeling tired
- pain in muscles, bones, and joints
- itchy skin
- shortness of breath
- decreased appetite
- back pain
- upper respiratory tract infection
- abdominal pain
These are not all of the possible side effects of OPDIVO. Talk to your healthcare team for more information. You are encouraged to report negative side effects of prescription drugs to the FDA. Visit
You may also
report side effects to Bristol-Myers Squibb at 1-800-721-5072.
Talking with your doctor is key
Review a list of questions with your oncologist about whether
OPDIVO is right for you.